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Humbly, A.B. would like to dedicate this work to the late Rupert Timpl (1936–2003), a master in science and lifeAbstract The a/b dystroglycan (DG) complex links the extra-
cellular matrix to the actin cytoskeleton. The extensive glycosyl-
ation of a-DG is believed to be crucial for the interaction with its
extracellular matrix-binding partners. We characterized a mono-
clonal antibody, directed against the b-DG-binding epitope
(positions 550–565), which recognizes preferentially hypogly-
cosylated a-DG. In Western blot, the antibody was able to detect
a number of partially glycosylated a-DG isoforms from rat brain
and chicken skeletal muscle tissue samples. In addition, we dem-
onstrated its inhibitory eﬀect on the interaction between a- and
b-DG in vitro and preliminary immunostaining experiments sug-
gest that such hypoglycosylated a-DG isoforms could play a role
within cells.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Glycosylation1. Introduction
Dystroglycan (DG) is formed by two subunits, a- and b-DG,
derived from a precursor encoded by a gene that is highly con-
served in vertebrates [1]. a-DG is a peripheral membrane pro-
tein that interacts with several extracellular matrix molecules
[2]. Electron microscopy showed that a-DG has a dumbbell-
like shape in which two globular domains are separated by a
highly glycosylated mucin-like region [3]. This extensive and
heterogeneous glycosylation shell causes a-DG to migrate on
SDS–PAGE as a broad band, immunodetectable in Western
blots, displaying a relative molecular mass of 120–160 kDa
depending on the tissue source [4]. a-DG interacts non-cova-
lently with the transmembrane b-DG, whose cytodomain
binds dystrophin plus other cytosolic proteins [2]; the b-DG-
binding epitope of a-DG has been localized within its C-termi-
nus, between the amino acids 550 and 565 [5,6].*Corresponding author. Fax: +39 06 3053598.
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doi:10.1016/j.febslet.2004.10.111Hypoglycosylated a-DG has been found in congenital mus-
cular dystrophies with associated developmental brain defects
depending on genetic abnormalities of glycosyltransferases [7].
A reduced aﬃnity of hypoglycosylated a-DG for laminin was
also demonstrated [8]. However, the role played by DG for
muscle stability is still rather controversial. The overexpression
of a-DG in mdx mice (a widespread model for Duchenne mus-
cular dystrophy) has apparently no positive eﬀects [9]. On the
other hand, it was also shown that transgenic mice carrying a
speciﬁc mutation (Ser654 to Ala) aﬀecting a/b posttranslational
processing develop a muscular dystrophy characterized by a
defective a-DG glycosylation [10]. Moreover, point mutations
of several putative glycosylation sites along the core protein se-
quence alter processing and traﬃcking of the DG precursor
protein [11].
We produced a new monoclonal antibody directed against
the core protein of a-DG, exploiting as an antigenic epitope
its binding region for b-DG. This antibody recognizes prefer-
entially hypoglycosylated forms of a-DG and is also able to
inhibit the interaction between the DG subunits.2. Materials and methods
2.1. Monoclonal antibodies
The monoclonal antibodies were prepared according to standard
procedures [12]. We used a commercial synthetic peptide (from
Synt:em, France), spanning the 549–567 sequence of a-DG C-termi-
nus, in complex with keyhole limpet hemocyanin (KLH) to inoculate
BALB/c mice. The hybridomas were obtained fusing splenocytes from
four immunized mice with myeloma SPO cells. Using a typical sequen-
tial ELISA screening protocol, we have selected a number of positive
hybridoma cell lines with a recombinant fragment corresponding to
the C-terminal domain of a-DG (485–600) [6]. The supernatant of
the most promising hybridoma cultures was collected and puriﬁed
using a HiTrap protein G column (Amersham, Sweden). The best
clone proved to be sx/3/50/25.
2.2. Preparation of a-DG from tissue samples
Native a-DG was isolated from both rat brain and chicken skeletal
muscle as described elsewhere [3]. Upon extensive dialysis against H2O,
the a-DG solution (10 ml) was lyophilized and a white granular pow-
der was directly used or stored in diﬀerent aliquots at 80 C. Lyoph-
ilized a-DG was resuspended in TBS, pH 7.4; the concentration was
determined with the Protein Assay kit (BioRad, UK). Western blotblished by Elsevier B.V. All rights reserved.
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erties of a-DG (data not shown). The whole DG complex (a plus b)
was enriched from the same tissues mentioned above according to
the established protocol [8]. All the recombinant DG fragments were
prepared and puriﬁed as described elsewhere [6].
2.3. Western blots
Mouse monoclonal antibody NCL-43DAG (clone8D5) (Novocastra
Laboratories Ltd., UK) was used to detect b-DG. a-DG was revealed
using mouse monoclonal antibody VIA4-1 (lot n 18428, Upstate Bio-
technology, USA), our newmonoclonal antibody sx/3/50/25 and a poly-
clonal antibody against the C-terminal of a-DG [13]. The samples were
subjected to SDS–PAGE; the percentage of acrylamide was 7.5% for
a-DG and 12% for b-DG, or a 7.5–15% gradient for both subunits.
For Western blot analysis, proteins were transferred to nitrocellulose
(100 V for 1 h). Unspeciﬁc binding sites were blockedwith 3%milk pow-
der in Tris-buﬀered saline (TTBS; 150 mMNaCl, 10 mMTris–HCl buf-
fer, pH 7.4, and 0.05%Tween 20) overnight at 4 Cand incubated for 1 h
with the primary antibody (1:25 forNCL-43DAG, 1.5lg/ml forVIA4-1,
1:100 for the polyclonal, all diluted in TBS containing 3% bovine serum
albumin and supernatant of hybridoma sx/3/50/25). After extensive
washing with TTBS, the nitrocellulose was incubated with horseradish
peroxidase-conjugated (Amersham, Sweden) secondary antibody di-
luted 1:5000 and the reactive products revealed using the luminol-based
ECL system (Pierce, USA) following the manufacturers instructions.2.4. Immunohistochemistry
Cryosections of human skeletal muscle (7 lm thick) were incubated
with PBS containing 1% BSA and 0.5% H2O2 for 30 min to block the
endogenous peroxidase activity. After washing with PBS, sections were
blocked with 3% BSA for 1 h at room temperature. Slides were then
incubated overnight with VIA1-4 (3 lg/ml), or 200 lg/ml of puriﬁed
IgG from sx/3/50/25 diluted in PBS and 3% BSA, or sx/3/50/25 hybrid-
oma. Slides were then rinsed with PBS and incubated for 1 h with sec-
ondary antibody (1:500) conjugated with horseradish peroxidase
(Amersham, Sweden). Sections were then treated with PBS containing
0.02% 3.3 0-diaminobenzadine tetrahydrochloride (DAB, Sigma, USA)
and 0.05% H2O2 for 10 min and then washed oﬀ with distilled water.2.5. Cell culture, transfection and immunolocalization of DG
293-Ebna cells were grown in DMEM supplemented with antibiotics
and 10% fetal calf serum. A DNA fragment corresponding to the
whole murine DG sequence, including its signal peptide, was ampliﬁed
from C2C12 muscle cells as previously described [14], employing as
forward primer Mstart 5 0-CCCGAATTCATGTCTGTGGACAA-
CTGGCTACTG-3 0 and as reverse primer Mstop 5 0-CCCGAATTCT-
TAAGGGGGAACATACGGAGGGGG-3 0 (EcoRI restriction sites
underlined). The construct was cloned into the pcDNA3 expression
vector (Stratagene,USA) and its sequence veriﬁed by automated
sequencing. pcDNA3DG was transiently transfected into Ebna-293
cells using Fugene-6 (Roche, Switzerland), according to the manufac-
turers instructions. After transfection (48 h), cells were ﬁxed with 4%
paraformaldehyde at room temperature for 30 min. For intracellular
staining, cells were permeabilized with PBS containing 0.1% saponin
and 5% BSA (Permeabilization Buﬀer, PB) for 30 min and then incu-
bated overnight with anti b-DG NCL-43DAG (1:25) or with the
monoclonal antibody sx/3/50/25 (used as hybridoma supernatant di-
luted 1:1 with PB). Cells were then incubated with 10 lg/ml Texas
Red-labeled secondary antibody (Vector Labs, USA) for 1 h at room
temperature and observed under a ﬂuorescence microscope (Zeiss,
Germany).
2.6. Solid-phase binding assays
Solid-phase binding assays were carried out as described elsewhere
[6]. Brieﬂy, for inhibition experiments, the microtiter plate wells were
incubated with increasing concentrations of biotinylated ligands,
b-DG (654–750) [6] or laminin-1 (Sigma, USA), in the presence or in
the absence of monoclonal antibody sx/3/50/25. The bound fractions
were detected with alkaline phosphatase Vectastain AB Complex
(Vector Labs, USA). A solution of 5 mg of p-nitrophenyl phosphate
was used as substrate and the absorbance values were recorded at
405 nm. Data were processed and normalized as fractional saturation
(%) as previously described [6].3. Results
3.1. Preparation of a new monoclonal antibody directed against
the b-DG-binding epitope of a-DG
We have previously identiﬁed the b-DG-binding epitope
within the C-terminal globular region of a-DG between resi-
dues 550 and 565 [5,6]. We decided that such a-DG region
would be an interesting target site for monoclonal antibodies
preparation. Therefore, we have prepared mouse monoclonal
antibodies using hybridoma-based standard protocols (see
Section 2). Mice were immunized with a synthetic peptide cor-
responding to the 549–567 sequence of a-DG, which is identi-
cal in all the mammalian sequences analyzed so far, Fig. 1A
[15]. A BLAST search revealed the absence of any signiﬁcant
homology with other proteins within this region (data not
shown). The speciﬁcity of puriﬁed IgG fraction of the best
hybridoma clone selected, sx/3/50/25 (hereinafter anti a-DG
25/50), was tested by Western blot against a recombinant
a-DG C-terminal fragment comprising the antigenic epitope
(Fig. 1B).
3.2. Western blot analysis of brain and muscle tissue fractions
We have investigated by Western blots the anti a-DG 25/50
staining pattern of puriﬁed a-DG and of WGL-enriched DG
complex from diﬀerent tissues and species (see the puriﬁcation
details in Section 2). In a-DG samples puriﬁed from rat brain,
a major band is eﬃciently detected by anti a-DG 25/50 (Fig.
2A). Surprisingly, the relative molecular size (Mr) of this band,
67 kDa (arrow, Fig. 2A), is clearly reduced with respect to
the ‘‘traditional’’ highly glycosylated a-DG, whose size ranges
from 120 kDa (brain) to 160 kDa (skeletal muscle), recognized
by the commercially available antibody VIA4-1 (Fig. 2A). The
same band (plus a fainter one at about 42 kDa) is recognized
also by polyclonal antibodies that we had previously obtained
against the C-terminal domain of a-DG [13]. It is remarkable
that anti a-DG 25/50 does not recognize the fully glycosylated
a-DG in rat brain, whereas the VIA4-1 monoclonal can recog-
nize also the 67 kDa band, plus an additional and faint lower
band at about 50 kDa in rat brain (Fig. 2B), but not in chicken
skeletal muscle (Fig. 2B). It should be noted that for the Wes-
tern blot reported in Fig. 2B, a high amount of sample (9 lg)
was loaded.
A similar staining pattern emerged analyzing with the anti a-
DG 25/50 the WGL-enriched fractions obtained from chicken
skeletal muscle. In fact, the anti a-DG 25/50 does not detect
the highly glycosylated a-DG but reveals a major band at a
lower molecular mass of 109 kDa (arrow in Fig. 3A), and
the same band is also revealed by the VIA4-1 (Fig. 3A).
Diﬀerently from what was observed in the previous exper-
iment, when loading increased amounts of sample (9 lg) and
by running a 7.5–15% acrylamide gradient SDS–PAGE,
additional bands were detected by both antibodies: a band
higher than 109 kDa, and a series of bands (all below 66
kDa) which might eventually originate from proteolytic deg-
radation (Fig. 3B). We cannot rule out if C-terminal (and
glycosylated) bands are generated during the sample prepara-
tion. Interestingly, a faint signal at 160 kDa, which could
indeed correspond to highly glycosylated a-DG, is also
detectable with anti a-DG 25/50 (asterisk in Fig. 3B). In
Fig. 3C is also reported the signal detected for b-DG using
NCL-43DAG, therefore conﬁrming that the WGL-enriched
fraction indeed contains b-DG.
Fig. 1. (A) Schematic representation of the DG complex. The box shows an alignment of the region 546–567, belonging to the C-terminal domain of
a-DG, that was used as target for the production of monoclonal antibody. (B) Western blot upon 12% SDS–PAGE of recombinant fragment Trx-a-
DG(485–600), 7.5 lg for each lane. Lane 1: Trx-a-DG(485–600) detected with the hybridoma supernatant; lane 2: with 5 lg/ml of puriﬁed IgG; lane
3: with 10 lg/ml; lane 4: with 20 lg/ml.
Fig. 2. (A) Western blot upon 7.5% SDS–PAGE of puriﬁed a-DG from rat brain. Lanes 1–4 a-DG (6 lg). Lane 1: detected with polyclonal antibody
anti a-DG C-terminal (1:100); lane 2: with IgG puriﬁed 25/50 (20 lg/ml); lane 3: with IgG puriﬁed 25/50 (10 lg/ml); lane 4: with the 25/50 hybridoma
supernatant; lane 5: a-DG (1.5 lg) detected with anti a-DG mAb VIA4-1 (1.5 lg/ml). (B) Western blot upon 7.5–15% gradient SDS–PAGE of
puriﬁed a-DG detected with anti-a-DG mAb VIA4-1 (1.5 lg/ml). Lane 1: a-DG (9 lg) from rat brain; lane 2: a-DG (9 lg) from chicken skeletal
muscle.
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Fig. 3. Western blot of the WGL-fraction obtained from chicken skeletal muscle. (A) 7.5% SDS–PAGE (5 lg for each lane). Lane 1: detected with
anti a-DG VIA4-1 (1.5 lg/ml); lane 2: with 25/50 (hybridoma). (B) 7.5–15% SDS–PAGE (10 lg). Lane 1: detected with 25/50 (hybridoma); lane 2:
with VIA4-1 (1.5 lg/ml). (C) 12% SDS–PAGE (5 lg): b-DG was detected using mAb anti b-DG (1/25).
Fig. 4. Immunohistochemistry of human skeletal muscle tissue
sections: VIA1-4 3 lg/ml (A), 25/50 hybridoma (B), 200 lg/ml of
puriﬁed IgG from 25/50 (C), secondary antibody 1:500 (D).
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We tested whether anti a-DG 25/50 was able to recognize a-
DG in human skeletal muscle cryosections. Anti a-DG 25/50
produces a staining pattern similar to VIA4-1, but displaying
a reduced intensity (Fig. 4A and B). A much lower signal
was detected with aﬃnity puriﬁed IgG compared to that of
25/50 hybridoma (Fig. 4B and C). We also tested anti a-DG
25/50 on human 293-Ebna cells. At the cell surface of non-
transfected cells, only faint and weak signals originating from
endogenous a-DG were observed (data not show). Moreover,
an irregular and diﬀused staining, diﬀerent from the typical
pattern obtained with VIA4-1, was obtained on transfected
cells (data not shown). Anti b-DG was used to show the stain-
ing pattern of typical DG-transfected cells (Fig. 5A and B). It
is interesting that a staining pattern was observed using anti
a-DG 25/50 in permeabilized 293-Ebna cells, both in non-
transfected and transiently transfected with the full-length
murine DG gene (Fig. 5C and D). Anti a-DG 25/50 produces
some perinuclear and/or vesicular signals that can be clearly
evidenced in transfected cells (Fig. 5D, see inset).
3.4. Solid-phase binding assays
The monoclonal antibody anti a-DG 25/50 was able to sig-
niﬁcantly inhibit the interaction of the biotinylated recombi-
nant extracellular domain of b-DG (654–750) with both
native a-DG and a recombinant C-terminal fragment (485–
600) of a-DG (Fig. 6A). However, anti a-DG 25/50 did not af-
fect the interaction between chicken skeletal muscle a-DG and
laminin-1 (Fig. 6B), which is likely to involve the N-terminal
region of a-DG [16].4. Discussion
4.1. Partially glycosylated isoforms of a-DG are
immunodetectable in several tissue sources
The new monoclonal antibody here described proved a very
useful tool for a deeper molecular analysis of the DG complex.
Somehow unexpectedly, the results clearly indicate that aside
Fig. 5. Immunoﬂuorescence localization of b-DG with anti 43-DAG
and of a-DG with anti a-DG 25/50 in permeabilized 293-Ebna cells
(63·), (A) non-transfected and (B) transiently transfected cells with
full-length murine DG stained with anti NCL-43DAG. (C) Non-
transfected and (D) transiently transfected cells with full-length murine
DG stained with anti a-DG 25/50. The inset shows an enlarged image
of a transfected cell displaying a perinuclear (arrowheads) and
vesicular (star) staining patterns.
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a-DG [1], partially glycosylated a-DG isoforms are stably ex-
pressed within cells; a notion that may have important reper-
cussions within the whole research ﬁeld [7].
In light of the Western blot results (Figs. 2 and 3), we may
consider the following points. First, it was already reported
that the full chemical deglycosylation of a-DG, achieved by
a treatment with TMSA, generates a band with a Mr of 72
kDa, likely corresponding to the core protein [17]. Such size
is similar to what we have estimated (67 kDa, see Fig. 2)
for the isoform identiﬁed in rat brain. It should be noted that
exactly the same band (67 kDa) was detected in rat brain
using a totally diﬀerent antibody, a polyclonal antibody raised
against a recombinant fragment spanning the whole C-termi-
nal region of a-DG, a-DGC (485–651) (Fig. 2A) [13]. More-Fig. 6. Solid-phase binding assays. (A) Biotinylated b-DG(654–750) bindi
Inhibition: binding to chicken skeletal muscle a-DG (n) and to a-DGC(485–
supernatant, respectively). (B) Control: biotinylated laminin-1 binding to c
dilution) (m).over, we observed an additional major band (109 kDa, see
Fig. 3) plus a series of bands in the range of 40–70 kDa also
in the WGL-fraction from chicken skeletal muscle. In this case,
we applied a fractioning protocol employing a WGL-resin
which binds with high aﬃnity sugar groups displayed by a-
DG. Strikingly, all these bands are detected not only by anti
a-DG 25/50 but also by a commercially available monoclonal
antibody directed against unknown glycan structures of a-DG,
VIA4-1 (see Fig. 2B). Taken together, these evidences clearly
indicate that the a-DG isoforms identiﬁed in diﬀerent tissue
sources are indeed partially glycosylated.
It is noteworthy that the major bands of 67 kDa in rat
brain and 109 kDa in chicken skeletal muscle show a similar
reduction of the molecular mass (of 50 kDa) when compared
to the highly glycosylated a-DG, 120 kDa and 160 kDa in rat
brain and chicken skeletal muscle, respectively. A possible
explanation is that the lower Mr forms represent similar stable
intermediates generated along the glycosylation pathway
evolved in diﬀerent cell types and vertebrate species. However,
a certain degree of proteolytic processing of the a-DG mole-
cule cannot be ruled out, especially when considering the
67 kDa band which is slightly smaller than the core protein
(72 kDa). This hypothesis should be veriﬁed by further
experiments of microsequencing, that could be used also to
analyze the C-terminal and glycosylated fragments (both
25/50- and VIA4-1-positive), displaying lower molecular
masses, identiﬁed in Fig. 3B. It is worth pointing out that pro-
teolysis of the N-terminal region of fully glycosylated a-DG
has been recently observed in transfected cells [16].
There is not an easy explanation to the evidence that anti a-
DG 25/50 does not recognize the highly glycosylated a-DG in
Western blots. We investigated the possibility that it might de-
pend on electrostatic repulsions induced by the strong negative
charge of the sialic acid-rich carbohydrate moieties of a-DG
[18], which could disrupt the antigen–antibody complex when
working on nitrocellulose [19]. However, experiments carried
out at much lower ionic strength (15 mM NaCl) or using
a-DG samples treated with neuraminidase from Arthrobacter
ureafaciens did not conﬁrm such hypothesis (data not shown).
Diﬀerently from VIA4-1, anti a-DG 25/50 produces weak
signals for endogenous a-DG at the plasma membrane ofng to chicken skeletal muscle a-DG (h) and a-DGC(485–600) (s).
600) (d) in the presence of 25/50 (1:1 and 1:4 dilutions of hybridoma
hicken skeletal muscle a-DG (M) and in the presence of 25/50 (1:1
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obtained either when staining transfected cells (data not
shown). It should be noted that the b-DG-binding epitope of
a-DG is buried within the DG complex and is potentially inac-
cessible for antibody targeting. Thus, it seems quite obvious
that the extensive carbohydrate moieties protruding from the
DG complex represent an easy-to-access and multivalent site
for an eﬃcient detection of a-DG with VIA4-1. The lower
aﬃnity displayed by a-DG 25/50 could also be explained by
the relatively low immunogenic capacity of the synthetic 19
aa peptide used to prepare the monoclonal antibody (Fig. 1).
Nevertheless, a preliminary analysis shows that anti a-DG
25/50 could be positively used for immunostaining of human
skeletal muscle tissue sections (Fig. 4). It is important to con-
sider that anti a-DG 25/50 could become an alternative tool
for the immunodetection of a-DG in tissue sections, speciﬁ-
cally in those from human patients aﬀected with secondary
defects of DG glycosylation (see below).
Our observations are in line with some recent work from
other laboratories [20,21]. Monoclonal antibody 1B7, targeting
the core protein of a-DG (positions 572–604), detects addi-
tional a-DG bands in diﬀerent tissue sources; it is noteworthy
that this antibody apparently recognizes highly glycosylated a-
DG in Western blots [20]. Some ‘‘functional variability’’ of the
antibodies directed against the core protein of a-DG (its C-ter-
minal domain in particular) may strongly depend on the par-
ticular linear epitope chosen. In another recent work [21],
aside from the ‘‘traditional’’ highly glycosylated 160 kDa band
of a-DG from rabbit skeletal muscle, an additional lower band
at 95 kDa is clearly detectable using glycoprotein staining
with PAS or overlay with a biotinylated perlecan domain
which shows a very high aﬃnity for a-DG [22]. Accordingly,
it is stated by the Authors that this additional band retains
the determinants for ligand binding [21]. Such band may rep-
resent a hypoglycosylated isoform eventually displaying some
degree of proteolysis [16].
4.2. New insights into a-DG?
Anti a-DG 25/50 may be helpful to shed some new light on
the structural-functional relationships of a-DG as suggested
by the solid-phase binding analysis (Fig. 6). The absence of
any observable inhibition of laminin-1 binding to a-DG in the
presence of diﬀerent amounts of anti a-DG 25/50, Fig. 6B, rein-
forces the notion that the N-terminal region of a-DG (including
the mucin-like region and its protruding carbohydrate moieties)
harbors its laminin-binding epitope, as previously hypothesized
[23], and recently conﬁrmed by others [16,24].
It is of particular interest that partially glycosylated a-DG
still binds with high aﬃnity perlecan domain V [21]. There-
fore, it is possible that some of the partially glycosylated
a-DG isoforms would still be able to play some role in the
cell and/or at the cell-basement membrane interface. The
most obvious hypothesis is that the a-DG isoforms are also
located at the peripheral side of the cell surface, as is the
highly glycosylated a-DG (see Fig. 4). However, they could
also represent partially glycosylated precursors, as suggested
by the internal staining obtained with anti a-DG 25/50 (Fig.
5C and D). It is intriguing that recently it was shown how
the phosphorylation of the b-DG cytodomain leads to the
re-distribution of b-DG within some cytosolic lipidic vesicles
[25] and a-DG-GFP signals have been localized within per-
meabilized ﬁbroblasts [26]. In this respect, it is likely thatthe entire DG complex behaves in a more dynamic fashion
than previously expected.
It is noteworthy that a number of muscular dystrophies and
myopathies depending on genetic abnormalities of a panel of
genes encoding for glycosyltransferases have been recently
identiﬁed [27,28]. The glycosylation defect of a-DG has been
considered as one of the primary molecular event responsible
for the observed pathologies within muscle ﬁbers [8]. More-
over, a-DG displays an altered expression pattern in some car-
cinoma cell lines and cancer tissues [29,30]. The increasing
interest in the molecular characterization of a-DG in neuro-
muscular diseases, or in other pathological conditions will re-
quire new investigation tools, such as monoclonal antibodies,
speciﬁcally recognizing the diﬀerent domains of the receptor
in order to better elucidate its biological role. It is noteworthy
to point out that the anti a-DG 25/50 antibody inhibits a/b
DG subunit interaction and it could be useful to investigate
the cellular signal transduction pathway aﬀected by disrupting
a/b DG binding. The careful analysis of samples obtained
from human patients aﬀected by neuromuscular or neoplastic
pathologies will be necessary to test whether the anti a-DG
25/50 antibody may represent a new valuable tool, not only
for biochemical studies, but also for molecular pathologists.Acknowledgments: We thank Aldobrando Broccolini and Enzo Ricci
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